VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DR. BOND who wrote (2711)	11/20/1997 3:31:00 PM
From: Sal Milani	Read Replies (1) of 23519

To all: I sent the following to the Wall Street Journal: >>Re: WSJ 11/18/97 "Schering-Plough Enters License Accord With Zonagen for Anti-Impotence Drug", by Robert Langreth As a shareholder in Vivus, I was disappointed that you did not mention the MUSE treatment for male impotency. You mentioned "existing therapies are cumbersome, typically involving injections into the penis." MUSE is not an injection. It uses a tiny suppository which is inserted in the urethra. In Vivus's first nine months of production it's sales were over $100 million and it is expanding production capacity several fold to keep up with demand. It seems that it should have at least been mentioned in your report.<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next